About UsMay 19 is National Asian and Pacific Islander HIV/AIDS Awareness Day
- Details
- Category: Race/Ethnicity
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
This Sunday, May 19, marks the 9th annual observation of National Asian and Pacific Islander HIV/AIDS Awareness Day, an occasion to increase awareness of HIV within these communities and stress the importance of testing and treatment.
Sangamo Reports Zinc Finger Gene Therapy Leads to Long-term CD4 Cell Gains, Shrinking HIV Reservoirs
- Details
- Category: Search for a Cure
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
An experimental gene therapy technique that modifies CD4 T-cells to protect them from viral entry produced lasting CD4 cell increases with a single infusion, as well as reduction in proviral DNA reservoirs and decreased viral load in 2 patients who underwent antiretroviral therapy (ART) interruption, according to data presented this week at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City.
FDA Declines Approval of Elvitegravir and Cobicistat as Stand-alone HIV Meds
- Details
- Category: HIV Treatment
- Published on Tuesday, 07 May 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) has rejected approval of Gilead Sciences' integrase inhibitor elvitegravir and pharmacoenhancer cobicistat -- components of the 4-in-1 Stribild quad pill -- as single agents for treatment of HIV, the company announced last week.
Very Early Antiretroviral Therapy Does Not Prevent Immune Activation
- Details
- Category: Search for a Cure
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
People who started antiretroviral therapy (ART) during acute HIV infection and experienced sustained viral suppression saw a substantial decrease in immune activation markers on their CD8 T-cells after 2 years of treatment, but often not to the level seen in HIV negative individuals, according to a report in the April 15, 2013, Journal of Acquired Immune Deficiency Syndromes.
U.S. Preventive Services Task Force Recommends Routine HIV Screening for Adolescents and Adults
- Details
- Category: HIV Testing & Diagnosis
- Published on Friday, 03 May 2013 00:00
- Written by Liz Highleyman
On April 30 the U.S. Preventive Services Task Force (USPSTF) issued a "Grade A," or highest-level, recommendation that all adolescents and adults ages 15 through 65 years should receive routine HIV screening. "These recommendations...reinforce the importance of people everywhere knowing their HIV status and, if positive, accessing care, receiving treatment and other prevention services," said CDC's Jonathan Mermin.
Updated Opportunistic Infection Guidelines Add Info on IRIS, Hepatitis, Drug Interactions
- Details
- Category: HIV Treatment Guidelines
- Published on Thursday, 09 May 2013 00:00
- Written by Liz Highleyman
On May 7 the National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Diseases Society of Americaannounced the release of revised Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, updating the previous version from 2009.
FDA Approves Efavirenz (Sustiva) for HIV+ Children Ages 3 Months to 3 Years
- Details
- Category: HIV Treatment
- Published on Friday, 03 May 2013 00:00
- Written by Bristol-Myers Squibb
The U.S. Food and Drug Administration (FDA) announced on May 3 that it has approved a supplemental new drug application for use of efavirenz (Sustiva) by infants and young children with HIV. The new dosing recommendation includes the option to sprinkling capsule contents on food for children who are unable to swallow pills.
Efavirenz More Effective than Nevirapine for Children with HIV
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 09 May 2013 00:00
- Written by Children’s Hospital of Philadelphia
HIV positive African children and adolescents treated with efavirenz (Sustiva) were less likely to experience virological failure than those using nevirapine (Viramune), according to a large comparative study published in the May 1, 2013, Journal of the American Medical Association. Nevirapine, however, is less expensive and more widely available for children in low-income countries.
Atripla Label Adds Drug Interactions with Hepatitis C Protease Inhibitors Boceprevir and Telaprevir
- Details
- Category: HIV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) announced this week that the product label information for Atripla -- the HIV single-tablet regimen containing efavirenz/tenofovir/emtricitabine -- has been updated to include information about drug-drug interactions with the hepatitis C virus protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek or Incivo).
Web Design and Development by